This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Saji, M. Articles by Zeiger, M. A. Search for Related Content PubMed PubMed Citation Articles by Saji, M. Articles by Zeiger, M. A.

Human Telomerase Reverse Transcriptase (hTERT) Gene Expression in Thyroid Neoplasms¹

Departments of Surgery [M. S., S. X., C-K. L., R. U., M. A. Z.], Pathology [W. H. W., D. P. C.], and Oncology [C. B. U., S. S.], The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287

Ten percent of fine-needle aspirations (FNAs) of the thyroid are deemed "indeterminate" or "suspicious" for malignancy by the cytopathologist, but most of these lesions are benign. Therefore, additional markers of malignancy may prove to be a useful adjunct.

The catalytic component of telomerase, human telomerase reverse transcriptase (hTERT), has been found to be reactivated in immortalized cell lines. Reverse transcription-PCR of the hTERT gene revealed expression in 15 (79%) of 19 malignant thyroid neoplasms, including 6 of 6 follicular carcinomas and 9 of 13 papillary carcinomas. In contrast, hTERT gene expression was detected in only 5 (28%) of 18 benign thyroid nodules, including 2 of 7 follicular adenomas and 3 of 11 hyperplastic nodules. All five benign thyroids exhibiting hTERT gene expression had lymphocytic thyroiditis. No normal thyroids exhibited hTERT gene expression. Telomerase enzyme activity was examined in all 37 nodules and was found to correlate with hTERT gene expression in 35 (95%) nodules. The two cases in which telomerase activity and hTERT expression results were discrepant were in two papillary carcinomas that were telomerase activity negative and hTERT positive. Finally, we have demonstrated that hTERT gene expression can be measured in in vivo FNA samples. These results suggest that hTERT expression may be more accurate than telomerase activity in distinguishing benign from malignant and may be measured in FNA samples from suspicious thyroid lesions.

This article has been cited by other articles:

				T. Foukakis, A. Gusnanto, A. Y. Au, A. Hoog, W.-O. Lui, C. Larsson, G. Wallin, and J. Zedenius A PCR-based expression signature of malignancy in follicular thyroid tumors Endocr. Relat. Cancer, June 1, 2007; 14(2): 381 - 391. [Abstract] [Full Text] [PDF]

				E Saggiorato, R De Pompa, M Volante, S Cappia, F Arecco, A P Dei Tos, F Orlandi, and M Papotti Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application Endocr. Relat. Cancer, June 1, 2005; 12(2): 305 - 317. [Abstract] [Full Text] [PDF]

				F. Weber, L. Shen, M. A. Aldred, C. D. Morrison, A. Frilling, M. Saji, F. Schuppert, C. E. Broelsch, M. D. Ringel, and C. Eng Genetic Classification of Benign and Malignant Thyroid Follicular Neoplasia Based on a Three-Gene Combination J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2512 - 2521. [Abstract] [Full Text] [PDF]

				C. B. Umbricht, G. T. Conrad, D. P. Clark, W. H. Westra, D. C. Smith, M. Zahurak, M. Saji, R. C. Smallridge, S. Goodman, and M. A. Zeiger Human Telomerase Reverse Transcriptase Gene Expression and the Surgical Management of Suspicious Thyroid Tumors Clin. Cancer Res., September 1, 2004; 10(17): 5762 - 5768. [Abstract] [Full Text] [PDF]

				C. Boltze, J. Mundschenk, N. Unger, R. Schneider-Stock, B. Peters, C. Mawrin, C. Hoang-Vu, A. Roessner, and H. Lehnert Expression Profile of the Telomeric Complex Discriminates between Benign and Malignant Pheochromocytoma J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4280 - 4286. [Abstract] [Full Text] [PDF]

				C. B. Barden, K. W. Shister, B. Zhu, G. Guiter, D. Y. Greenblatt, M. A. Zeiger, and T. J. Fahey III Classification of Follicular Thyroid Tumors by Molecular Signature: Results of Gene Profiling Clin. Cancer Res., May 1, 2003; 9(5): 1792 - 1800. [Abstract] [Full Text] [PDF]

				F. Buttitta, C. Pellegrini, A. Marchetti, A. Gadducci, S. Cosio, L. Felicioni, F. Barassi, S. Salvatore, C. Martella, G. Coggi, et al. Human Telomerase Reverse Transcriptase mRNA Expression Assessed by Real-Time Reverse Transcription Polymerase Chain Reaction Predicts Chemosensitivity in Patients With Ovarian Carcinoma J. Clin. Oncol., April 1, 2003; 21(7): 1320 - 1325. [Abstract] [Full Text] [PDF]

				L. Teng, M. C. Specht, C. B. Barden, and T. J. Fahey III Antisense hTERT Inhibits Thyroid Cancer Cell Growth J. Clin. Endocrinol. Metab., March 1, 2003; 88(3): 1362 - 1366. [Abstract] [Full Text] [PDF]

				V. J. Bernet, J. Anderson, Y. Vaishnav, B. Solomon, C. F. Adair, M. Saji, K. D. Burman, H. B. Burch, and M. D. Ringel Determination of Galectin-3 Messenger Ribonucleic Acid Overexpression in Papillary Thyroid Cancer by Quantitative Reverse Transcription-Polymerase Chain Reaction J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4792 - 4796. [Abstract] [Full Text] [PDF]

				T. Takano, A. Miyauchi, F. Matsuzuka, K. Kuma, and N. Amino Expression of Oncofetal Fibronectin Messenger Ribonucleic Acid in Fibroblasts in the Thyroid: A Possible Cause of False Positive Results in Molecular-Based Diagnosis of Thyroid Carcinomas J. Clin. Endocrinol. Metab., February 1, 2000; 85(2): 765 - 768. [Abstract] [Full Text]